2021 update on thyroid-associated ophthalmopathy.
Neag EJ, Smith TJ.
J Endocrinol Invest. 2022 Feb;45(2):235-259. doi: 10.1007/s40618-021-01663-9. Epub 2021 Aug 20.
Cytokines in Thyroid-Associated Ophthalmopathy.
Zhang P, Zhu H.
J Immunol Res. 2022 Nov 14;2022:2528046. doi: 10.1155/2022/2528046. eCollection 2022.
Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
Smith TJ, Janssen JAMJL.
Endocr Rev. 2019 Feb 1;40(1):236-267. doi: 10.1210/er.2018-00066.
Thyroid-associated ophthalmopathy: the role of oxidative stress.
Ma C, Li H, Lu S, Li X.
Front Endocrinol (Lausanne). 2024 Jul 11;15:1400869. doi: 10.3389/fendo.2024.1400869. eCollection 2024.
Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
Smith TJ.
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101383. doi: 10.1016/j.beem.2020.101383. Epub 2020 Jan 31.
Advances in artificial intelligence in thyroid-associated ophthalmopathy.
Yi C, Niu G, Zhang Y, Rao J, Liu G, Yang W, Fei X.
Front Endocrinol (Lausanne). 2024 Apr 23;15:1356055. doi: 10.3389/fendo.2024.1356055. eCollection 2024.
Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy.
Smith TJ.
Ophthalmic Plast Reconstr Surg. 2023 Dec 1;39(6S):S9-S18. doi: 10.1097/IOP.0000000000002509. Epub 2023 Dec 4.
Thyroid-associated ophthalmopathy and ferroptosis: a review of pathological mechanisms and therapeutic strategies.
Ma C, Li H, Lu S, Li X.
Front Immunol. 2024 Dec 6;15:1475923. doi: 10.3389/fimmu.2024.1475923. eCollection 2024.
Graves' ophthalmopathy.
Bahn RS.
N Engl J Med. 2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.
Treating Thyroid Associated Ophthalmopathy in Pediatric Patients.
Dong T, Fu Z, Wang X.
Front Endocrinol (Lausanne). 2022 Jun 28;13:900204. doi: 10.3389/fendo.2022.900204. eCollection 2022.
